|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Comparison between different femoral fixation devices for ACL Reconstruction with doubled hamstring tendon graft:a biomechanical analysis显示文摘 | Milano G Mulas PD Ziranu F | | 0，，06： | 1 |
| 2 | Comparison between different femoral fixation devices for ACL reconstruction with doubled hamstring tendon graft:a biomechanical analysis显示文摘 | Milano G Mulas PD Ziranu F | 2006 | Arthroscopy2006，22，6： | 1 |
| 3 | Comparison of femoral fixation methods for anterior cruciate ligament reconstruction with patellar tendon graft:a mechanical analysis in porcine knees显示文摘 | Milano G Mulas PD Ziranu F | 2007 | Knee Surg Sports Traumatol Arthrosc2007，15，6： | 1 |
| 4 | Comparison between different femoral fixation devices for ACL reconstruction with doubled hamstring tendon graft: a biomeehanical analysis 显示文摘 | Milano G Mulas PD Ziranu F | 2006 | Arthroscopy2006，22，6： | 1 |
| 5 | Comparison of femoral fixa- tion methods for anterior crueiate ligament reeonstmetion with pa tellar tendon graft a mechanical analysis in porcine knees显示文摘 | Milano G Mulas P D Ziranu F | 2007 | Knee Surg Sports Traurnatol Arthrosc2007，15，6： | 1 |
| 6 | Comparison between differentfemoral fixation devices for ACL reconstruction with doubled ham-string tendon graft:a biomechanical analysis显示文摘 | Milano G Mulas PD Ziranu F | 2006 | Arthroscopy2006，22，6： | 1 |
| 7 | Comparison between different femoral f'txation devices for ACL reconstruction with doubled ham- string tendon graft:a biomechanical analysis 显示文摘 | Milano G Mulas PD Ziranu F | 2006 | Arthroscopy2006，22，6： | 1 |
| 8 | Comparison between different femoral fixation devices for ACL reconstruction with doubled hamstring tendon graft:a biomechanical analysis显示文摘 | Milano G Mulas PD Ziranu F | 2006 | Arthroscopy2006，22，6： | 1 |
| 9 | Comparison between different femoral fixation devices for ACL reconstruction with doubled hamstring tendon graft:a biomechanical analysis显示文摘 | Milano G Mulas PD Ziranu F | 2006 | Arthroscopy2006，22，6： | 1 |
| 10 | Acrometastasis:a literature review显示文摘 | Stomeo D Tulli A Ziranu A | 2005 | Eur Rev Med Pharmacol Sci2005，19，5： | 1 |
| 11 | Comparison between different femoral fixation device for ACL reconstruction with doubled hamstring tendon graft:a biomechanical analysis显示文摘 | Hano G Mulas PD Ziranu F | 2006 | Arthroscopy2006，22，6： | 1 |
| 12 | A rare case of iliac crest metastasis from acinic cell carcinoma of parotid gland显示文摘 | SESSA S ZIRANU A DI GIACOMO G | 2014 | World J Surg Oncol2014，12，： | 1 |
| 13 | Comparison of femoral fixation methods for anterior cruciate ligament Reconstruc- tion with patellar tendon graft:a mechanical analysis in por- cine knees 显示文摘 | Milano G Mulas PD Ziranu F | 2007 | Knee Surg Sports Traumatol Arthrosc2007，15，6： | 1 |
| 14 | Comparison Between differert femoral fixation devices for ACL reconstruction with doubled hamstring tendon graft:a biomechanical analysis显示文摘 | Milano G Mulas PD Ziranu F | | 0，，： | 1 |
| 15 | Comparison between differentfemoral fixation devices for ACL reconstruction with doubled hamstringtendon graft:a biomechanical analysis显示文摘 | Milano G Mulas PD Ziranu F | 2006 | Arthroscopy2006，6，： | 1 |
| 16 | Comparison between different femoral device for ACL reconstruction with doubled hamstring tendon graft:a biomechanical analysis 显示文摘 | Milano G Mulas PD ziranu F | 2006 | Arthroscopy2006，22，6： | 1 |
| 17 | Comparison between different femoral fixation devices for ACL reconstruction with doubled hamstring tendon graft: a biomechanical analysis显示文摘 | Milano G Mtflas PD Ziranu F | 2006 | Arthroscopy2006，22，6： | 1 |
| 18 | Circulating tumour DNA in gastrointestinal cancer in clinical practice:Just a dream or maybe not?显示文摘The evaluation of circulating tumor DNA(ctDNA)is increasingly integrated into the management of diagnosis and treatment of gastrointestinal cancer as it represents an innovative and minimally invasive biomarker that could allow us to reach clinical needs not met yet in randomized clinical trials.Recent research provided an interesting overview of the role of circulating tumor DNA in gastric,biliary,liver,pancreatic,and colorectal cancer.Data regarding upper gastrointestinal tumors are currently not practice changing.Tumor detection rates are low in the early stages,while in advanced stages ctDNA is useful for molecular tracking evaluation.Most of the evidence comes from colorectal cancer studies,where ctDNA was evaluated both in the early and advanced stages with the postsurgery minimal residual disease assessment and the response assessment,respectively.ctDNA qualifies as a promising tool in the era of precision medicine,with potential applications in the entire management of gastrointestinal cancer patients.Further evidence is needed to establish which setting may be influenced greatly by liquid biopsy in clinical practice. | Andrea Pretta Eleonora Lai Clelia Donisi Dario Spanu Pina Ziranu Valeria Pusceddu Marco Puzzoni Elena Massa Mario Scartozzi | 2022 | World Journal of Clinical Oncology2022，13，12： | 0 |
| 19 | How to improve metastatic pancreatic ductal adenocarcinoma patients’selection:Between clinical trials and the real-world显示文摘As underlined in the minireview by Blomstrand et al,given the poor prognosis and the paucity of data on a therapeutic sequence in pancreatic ductal adenocarcinoma(PDAC),additional randomized controlled trials and real-world evidence studies addressing current and novel regimens are needed.The real-world outcomes of first-line chemotherapy regimens such as FOLFIRINOX and gemcitabine/nab-paclitaxel are thoroughly reviewed and seem to be largely generalizable in a real-world context.Regarding second-line chemotherapy,the key question about the optimal sequence of regimens remains uncertain.Precisely in this setting,it is therefore useful to encourage the implementation of clinical studies that may contribute to the scarcity of data available up to now.We report our experience with a small group of patients treated with second-line liposomal irinotecan(nal-IRI)plus 5-fluorouracil and leucovorin.To improve the treatment of patients affected by PDAC,it is useful to identify subgroups of patients who may benefit from target treatments(e.g.,BRCA mutant)and it is also important to focus on any prognostic factors that may affect the survival and treatment of these patients. | Andrea Pretta Dario Spanu Stefano Mariani Nicole Liscia Pina Ziranu Valeria Pusceddu Marco Puzzoni Elena Massa Mario Scartozzi Eleonora Lai | 2022 | World Journal of Clinical Oncology2022，13，5： | 0 |
| 20 | Hepatocellular carcinoma and microbiota:Implications for clinical management and treatment显示文摘Gut microbiota plays an essential role in host homeostasis.It is involved in several physiological processes such as nutrients digestion and absorption,maintenance of intestinal epithelial barrier integrity and immune system self-tolerance.Especially the gut microbiota is assumed to play a crucial role in many gastrointestinal,pancreatic and liver disorders.Its role in hepatic carcinogenesis is also gaining increasing interest,especially regarding the development of therapeutic strategies.Different studies are highlighting a link between some bacterial strains and liver disease,including hepatocellular carcinoma(HCC).Indeed,HCC represents an interesting field of research in this perspective,due to the gut-liver axis,to the implication of microbiota in the immune system and to the increasing number of immunotherapy agents investigated in this tumour.Thus,the assessment of the role of microbiota in influencing clinical outcome for patients treated with these drugs is becoming of increasing importance.Our review aims to give an overview on the relationship between microbiota and HCC development/progression and treatment.We focus on potential implications on the available treatment strategies and those under study in the various stages of disease.We highlight the pathogenic mechanisms and investigate the underlying molecular pathways involved.Moreover,we investigate the potential prognostic and/or predictive role of microbiota for target therapies,immune checkpoint inhibitors and loco-regional treatment.Finally,given the limitation of current treatments,we analyze the gut microbiota-mediated therapies and its potential options for HCC treatment focusing on fecal microbiota transplantation. | Dario Spanu Andrea Pretta Eleonora Lai Mara Persano Clelia Donisi Stefano Mariani Marco Dubois Marco Migliari Giorgio Saba Pina Ziranu Valeria Pusceddu Marco Puzzoni Giorgio Astara Mario Scartozzi | 2022 | World Journal of Hepatology2022，14，7： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员